Nad+ Research Guide

Premium USA-Made Research Compounds

Browse lab-tested peptides, research liquids, capsules and more.

Table of Contents

NAD+ Research Guide: Cellular Energy, Sirtuin Activation & Longevity Mechanisms

For laboratory and research use only. Not for human consumption.

Middle age. Half your NAD+ — gone. In skin? It gets worse. Up to 80% depleted between your twenties and sixty. That’s not a minor biomarker shift. That’s a wholesale biochemical collapse.

NAD+ touches over 500 enzymatic reactions. Burns fuel (glycolysis, TCA cycle, oxidative phosphorylation). Activates sirtuins — the longevity enzymes. Powers PARP-mediated DNA repair. Connects energy metabolism to genome maintenance to aging itself. And it vanishes with every passing decade.

Looking for Premium Research Compounds?

🧪 Peptides 💧 Research Liquids 💊 Capsules 🛒 Full Catalog

What follows: NAD+ biochemistry from the ground up, sirtuin biology, the PARP competition problem, why CD38 is the real villain, mitochondrial connections, precursor strategies, and the preclinical longevity evidence. A lot to cover.

What Is NAD+?

Arthur Harden boiled yeast extract in 1906. Something in the filtrate made fermentation go faster. Small molecule. Heat-stable. They called it a “cozymase.” We call it NAD+.

Two nucleotides linked through phosphate groups — NMN on one side, AMP on the other. Deceptively simple for a molecule that participates in hundreds of reactions.

Molecular Formula: C₂₁H₂₇N₇O₁₄P₂
Molecular Weight: 663.43 g/mol
CAS Number: 53-84-9

Primary role: electron shuttle. Grabs hydride ions off metabolic substrates in glycolysis, TCA, and oxidative phosphorylation. Becomes NADH. The ratio between NAD⁺ and NADH tells cells what metabolic gear they’re running. High = active oxidation. Low = reduced state (Cantó et al., 2015; PMID: 25662603).

But the aging field doesn’t care about the electron shuttle role. It cares about what happens when NAD+ gets consumed. Three enzyme families — sirtuins, PARPs, CD38 — literally break NAD+ apart. They crack the nicotinamide-ADP-ribose bond and use the fragments for regulatory reactions (Imai & Guarente, 2014; PMID: 24786174).

This is the part people miss. NAD+ isn’t just an electron carrier. It’s expendable fuel for the cell’s highest-priority maintenance systems. And when levels drop with age, those systems starve.

Sirtuins: Why NAD+ Decline Kills Longevity Pathways

The sirtuin family. SIRT1 through SIRT7. Deacylases that yank acetyl and acyl groups off proteins — but only when NAD+ is available to power the reaction. Pull NAD+ away and sirtuin activity collapses. That’s not metaphor; it’s enzymology.

Sirtuin	Where	What It Does	Standout Data
SIRT1	Nucleus/Cytoplasm	Metabolic regulation	Hypothalamic overexpression → extended lifespan in mice (Satoh, 2013)
SIRT2	Cytoplasm	Cell cycle control	Mitotic checkpoints, adipocyte biology
SIRT3	Mitochondria	Mitochondrial deacetylation	Turns on SOD2, respiratory chain. Oxidative stress defense
SIRT4	Mitochondria	ADP-ribosylation	Glutamine metabolism, insulin secretion
SIRT5	Mitochondria	Desuccinylation	Urea cycle, fatty acid oxidation
SIRT6	Nucleus	DNA repair, telomeres	Transgenic overexpression → males lived longer (Kanfi, 2012)
SIRT7	Nucleolus	rDNA transcription	Ribosomal RNA, stress response

Here’s what makes this family so interesting for aging research. They’ve shown lifespan effects in yeast, C. elegans, flies, and mice. Four entirely different organisms. The through-line: stress resistance, antioxidant defenses (SOD2, IDH2), DNA repair, and protection against metabolic decline, cardiovascular problems, and neurodegeneration (Haigis & Sinclair, 2010; PMID: 20816999). Not one pathway. A whole web of them — all gated by NAD+ availability.

Also worth a look for longevity researchers: Epitalon (telomere biology) and MOTS-c (mitochondrial signaling peptide).

PARPs: The NAD+ Budget Problem

PARP1 and PARP2 do 90% of PARP activity in mammalian cells. Their job: DNA repair. When strand breaks show up, PARP1 arrives at the damage, cracks open NAD+ molecules, and builds poly(ADP-ribose) chains that flag the site for repair crews (Gibson & Kraus, 2012; PMID: 23152441). Crucial work. But incredibly expensive — measured in NAD+ molecules consumed.

Acute DNA damage can trigger PARP hyperactivation. When that happens? NAD+ reserves get torched. Rapidly. And every NAD+ molecule PARP burns is one the sirtuins can’t use.

Proof: PARP1 knockout mice. No PARP1 means no NAD+ drain from DNA repair. The result — systemically elevated NAD+, more SIRT1 activity, improved metabolic profiles across the board (Bai et al., 2011; PMID: 21321080). Chemical PARP inhibitors did the same thing. Block one NAD+ consumer, and the others feast.

This is the fundamental tension in NAD+ biology. PARPs, CD38, and sirtuins all compete for a limited NAD+ supply. A zero-sum game at the molecular level. Understanding who’s winning that competition at any given point in the aging process — that’s what drives the entire NAD+ repletion field (Mouchiroud et al., 2013; PMID: 23698361).

CD38 and the Age-Related NAD+ Collapse

CD38. Ectoenzyme. Chews through NAD+ and spits out cyclic ADP-ribose for calcium signaling. And its expression climbs — relentlessly — as organisms age. If you want a single culprit for age-related NAD+ loss, this is it.

The decline in numbers:

~50% of NAD+ gone by middle age (Yoshino et al., 2018; PMID: 29514064)
Skin by 60: 50–80% depleted (Massudi et al., 2012; PMID: 22848760)
Brain loses 10–25%. Liver about 30% (over-60 vs. under-45)
Men drop faster, especially mid-life

Knockout experiment: remove CD38 entirely from mice. NAD+ stays elevated. SIRT1 cranks up. High-fat-diet metabolic damage? Protected (Barbosa et al., 2007; PMID: 17376880).

Why does CD38 increase with age? Blame inflammaging. Chronic low-grade inflammation. Fewer NAD+ molecules → more senescent cells → more inflammatory cytokines → higher CD38 expression → even less NAD+. A self-reinforcing spiral that accelerates with every year.

Mitochondria Can’t Run Without It

Every time the TCA cycle turns, it produces NADH. That NADH hands electrons to Complex I — the biggest, first complex in the electron transport chain. Kill that handoff and ATP production collapses. No NAD+ recycling, no energy. Full stop.

Three specific connections:

When Complex I is deficient, NADH piles up because it can’t pass electrons forward. Mitochondrial NAD+ crashes. SIRT3 goes dark. Tissue damage follows. In cardiac models, giving NMN fixed the problem — replenished the NAD+, reactivated SIRT3, rescued the tissue (Karamanlidis et al., 2013; PMID: 24043299).

SIRT3 itself deacetylates subunits in both Complex I and Complex II. It’s the quality control enzyme for the respiratory chain. And it runs on NAD+. Low NAD+ means sloppy mitochondria.

Then there’s biogenesis — making entirely new mitochondria. SIRT1 deacetylates PGC-1α, which kicks off mitochondrial production. SIRT1 needs NAD+. So NAD+ levels control not just how well existing mitochondria work but how many new ones get built.

Related compounds for mitochondrial research: MOTS-c (AMPK pathway), Glutathione 600mg, and Glutathione 1500mg for redox/oxidative stress work alongside NAD+.

Preclinical Longevity Data

Here’s where NAD+ goes from interesting chemistry to “maybe we can reverse aging.”

Worms

Give C. elegans NAD+ precursors and block PARPs. The worm sirtuin (sir-2.1) fires up. Mitochondria work better. The worms live longer. Simple experiment, clear result: busted NAD+ metabolism causes aging phenotypes. It’s not just correlated — fix the NAD+ and you fix the decline (Mouchiroud et al., 2013; PMID: 23698361).

Old Mice

Late-middle-age mice. NMN dissolved in drinking water at 500 mg/kg/day. Insulin sensitivity bounced back. Lipid profiles cleaned up. Mitochondria hummed again. The animals moved more. Organ after organ reversed its age-related slide. That isn’t a targeted drug effect — it’s systemic metabolic rejuvenation from restoring one coenzyme (Mills et al., 2016; PMID: 27127236).

One Gene, Longer Life

Extra SIRT6 copies? Male mice lived longer. Lower IGF-1. Better metabolism. Just one sirtuin gene (Kanfi et al., 2012; PMID: 22367546). Target SIRT1 to the hypothalamus? Both sexes lived longer. Turns out the hypothalamus works as a longevity rheostat — and NAD+-dependent sirtuin activity is the dial (Satoh et al., 2013; PMID: 23746838).

Also in the longevity toolkit: Epitalon 10mg (telomerase) and animal study data.

NMN vs. NR vs. Direct NAD+

The precursor question. Three molecules, three routes to the same destination.

	NMN	NR	Direct NAD+
MW	334 g/mol	255 g/mol	663 g/mol
Conversion Steps	One (NMNAT)	Two (NRK → NMNAT)	Zero. Already NAD+
Oral Route	Fast absorption, salvage pathway	Phosphorylated before conversion	Big molecule — parenteral routes studied

Straightforward, right? Fewer steps should mean faster NAD+ elevation. Except a 2025 Science Advances paper complicated the picture. Both NMN and NR, when taken orally, get mostly broken down to plain nicotinamide (NAM) in the gut and liver first. Then re-synthesized into NAD+ through the Preiss-Handler pathway. The precursors themselves spiked in blood within 15 minutes — gone by 60. Actual NAD+ elevation was slower and more sustained (Yaku et al., 2025; DOI: 10.1126/sciadv.adr1538).

So much for the “direct conversion” narrative. The body routes things its own way.

Direct NAD+ 500mg administration bypasses all of that. It is the finished molecule. No enzymatic middlemen. The catch: 663 Da is nearly double the size of NMN, which complicates absorption. Parenteral delivery solves that, oral delivery doesn’t. Pick your trade-off based on protocol needs.

Safety and Practical Considerations

Generally favorable safety profile across preclinical models. NMN at 100–500 mg/kg/day in mice showed no significant adverse findings in long-term studies (Mills et al., 2016).

Watch for:

Metabolic flux shifts — raising NAD+ changes the competition between PARPs, sirtuins, and CD38 for the expanded pool. More sirtuin activity is the goal; reduced PARP capacity is the trade-off
NAD⁺/NADH ratio matters for protocol design. The oxidized-to-reduced balance influences multiple pathways simultaneously. Don’t ignore it
NAD+ degrades with light, heat, and pH extremes. Store properly or your measurements are artifacts

Regulatory Status

NAD+ is a research compound available for laboratory and investigational use. Not FDA-approved as a standalone agent. NAD+ and its precursors (NMN, NR) are available through research suppliers for preclinical work.

Research Availability

From Loti Labs:

NAD+ 500mg — $99.99
Glutathione 600mg — $89.99 (redox/antioxidant studies)
Glutathione 1500mg — $149.99 (intensive oxidative stress work)
Epitalon 10mg — $49.99 (telomerase/longevity)

Conclusion

NAD+ vanishes as we age. CD38 drives the loss. Sirtuins and PARPs fight over what remains. Mitochondria stall. The data isn’t ambiguous — it’s a cascade where one declining molecule triggers failures across energy production, genome maintenance, and longevity signaling simultaneously.

But give aging animals NAD+ back? Metabolism rebounds. Mitochondria fire up. Physical function returns. Multiple organ systems improve at once. That’s the preclinical promise — and it’s consistent across worms, mice, and every model organism tested so far.

Open questions remain. Delivery optimization. Tissue-specific kinetics. How much PARP capacity do you sacrifice for sirtuin gains? What’s the circadian angle? Big questions. But NAD+ left the “speculative” category years ago. This is bedrock aging biology now.